Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
JAMA Dermatol ; 150(5): 522-5, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24599332

RESUMO

IMPORTANCE: Tumor ulceration is an important prognostic factor for cutaneous melanoma (CM). Previous studies demonstrated that the proportion of ulcerated to nonulcerated CM rose with increasing tumor depth. These frequency-based studies, however, were not adjusted for the population at risk. OBJECTIVE: To determine the absolute incidence of ulcerated CM by tumor depth, stratified by sex and age at diagnosis. DESIGN, SETTING, AND PARTICIPANTS: We compared ulcerated CM by tumor thicknesses (≤1.00, 1.01-2.00, 2.01-4.00, and ≥4.01 mm), stratified by sex among younger (10-39 years) and older (40-84 years) non-Hispanic whites in the National Cancer Institute's Surveillance, Epidemiology, and End Results database from 2004 through 2008. Types of CM included superficial spreading, nodular, and unclassified in 5106 cases among 3206 men and 1900 women. MAIN OUTCOMES AND MEASURES: Incidence of ulcerated CM by tumor depth for younger and older men and women. RESULTS: The incidence of tumor ulceration was stable across all tumor depths among younger men and older women. Among younger women, it declined for the thickest lesions (0.08 per 100,000 for tumor depth ≥4.01 mm), although the trend was not statistically significant. In contrast, among older men, there was a statistically significant increase in ulceration for CM with a depth of approximately 1.4 per 100,000 for tumor depth of 2.00 mm or thicker. CONCLUSIONS AND RELEVANCE: Male sex is an age-specific effect modifier for ulcerated CM by tumor depth. Future studies and staging guidelines should consider the interaction among CM ulceration, thickness, sex, and age at diagnosis.


Assuntos
Melanoma/patologia , Neoplasias Cutâneas/patologia , Úlcera Cutânea/patologia , Adolescente , Adulto , Distribuição por Idade , Idoso , Idoso de 80 Anos ou mais , Biópsia por Agulha , Criança , Estudos Transversais , Bases de Dados Factuais , Progressão da Doença , Feminino , Humanos , Imuno-Histoquímica , Modelos Lineares , Masculino , Melanoma/epidemiologia , Melanoma/fisiopatologia , Pessoa de Meia-Idade , Invasividade Neoplásica/patologia , Estadiamento de Neoplasias , Valor Preditivo dos Testes , Prevalência , Prognóstico , Distribuição por Sexo , Neoplasias Cutâneas/epidemiologia , Neoplasias Cutâneas/fisiopatologia , Úlcera Cutânea/epidemiologia , Úlcera Cutânea/fisiopatologia , Adulto Jovem
2.
Clin Cosmet Investig Dermatol ; 3: 49-58, 2010 Apr 19.
Artigo em Inglês | MEDLINE | ID: mdl-21437059

RESUMO

Psoriasis is a chronic T-cell-mediated inflammatory disease that primarily affects the skin and joints. Patients with moderate to severe psoriasis constitute about 30% of the psoriasis population. Treatment of this group is challenging due to the long-term side effects, toxicities and inconvenience of conventional treatments such as phototherapy, methotrexate and cyclosporine. However, recent advances in our understanding of the pathogenesis of psoriasis have led to the popular use of biologics, which offer a safer, more convenient and effective targeted therapy. Adalimumab was originally approved for treating rheumatoid arthritis. Currently, adalimumab is also approved for treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy or when other systemic therapies are medically less appropriate. Since the onset of the use of biologics, there have been concerns over safety and efficacy when used as long-term therapy. This paper reviews all publications, posters and abstracts reporting original data on the efficacy and/or safety of adalimumab in patients treated for chronic plaque psoriasis for more than 1 year.

3.
J Am Osteopath Assoc ; 109(11): 605-8, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19948695

RESUMO

Notalgia paresthetica is a chronic sensory neuropathy characterized by pruritus of the upper to middle back, typically below the left shoulder blade. Symptoms may include pain, hyperesthesia, paresthesia, and hyperpigmentation of the affected area. Although the etiologic process of this condition is poorly understood, recent correlations with degenerative spinal changes suggest that spinal nerve impingement may play a role. The authors report the case of a 59-year-old woman with notalgia paresthetica who received one 20-minute session of osteopathic manipulative treatment that focused primarily on thoracic spine and rib somatic dysfunctions. After treatment, the patient reported immediate improvement of symptoms. A discussion of this condition based on previously published literature is also provided.


Assuntos
Dor nas Costas/terapia , Osteopatia , Parestesia/terapia , Acidentes de Trânsito , Dor nas Costas/diagnóstico , Feminino , Humanos , Hiperpigmentação/etiologia , Pessoa de Meia-Idade , Síndromes de Compressão Nervosa/diagnóstico , Síndromes de Compressão Nervosa/terapia , Parestesia/diagnóstico , Prurido/diagnóstico , Prurido/etiologia , Prurido/terapia
4.
J Clin Aesthet Dermatol ; 2(2): 26-31, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20967178

RESUMO

Mycetoma is a chronic and progressive subcutaneous granulomatous infection characterized by painless swelling and tumefaction, draining sinus tracts, and purulent discharge. The term eumycetoma is used to describe an infection caused by fungi, while an actinomycetoma is used to describe an infection caused by filamentous bacteria. An accurate identification of the pathogen plays a vital role in the treatment plan as well as a positive outcome for the patient. In this report, we present an elderly white female with an initial presentation of mycetoma masquerading as a squamous cell carcinoma. We also review microbiology, diagnostic modalities, and treatment for mycetoma.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...